olaratumab

Ligand id: 9172

Name: olaratumab

Classification
Compound class Antibody
Approved drug? Yes (FDA (2016))
International Nonproprietary Names
INN number INN
9308 olaratumab
Synonyms
IMC-3G3 | Lartruvo® | LY3012207
Database Links
Specialist databases
IMGT/mAb-DB 352
Other databases
GtoPdb PubChem SID 315661255
Search PubMed clinical trials olaratumab
Search PubMed titles olaratumab
Search PubMed titles/abstracts olaratumab
Comments
Olaratumab is a fully human anti-platelet-derived growth factor receptor α (PDGFRα) monoclonal antibody, developed by Eli Lilly (link to Lilly's olaratumab webpage here), originally developed by ImClone Systems, Inc. [2].
Peptide sequences and structural information for this antibody are available from its IMGT/mAb-DB record. BLAST peptide sequence analysis reveals identical matches with sequences 8 and 16 from patent US8128929, and directly to clone IMC-3G3 [1]. From patent US8128929 it appears that the epitope recognised by olaratumab overlaps the PDGFRα binding sites for PDGF-AA and PDGF-BB.